Biology subjects

Roepman, P.

Publications and source records attributed to Roepman, P..

3 recordsLinked to original sources

bioRxiv2026

The pan-cancer whole-genome landscape of Adolescent and Young Adult solid cancers

Cancer incidence in adolescents and young adults (AYAs; 18-39 years) is rising, but how their tumors differ genomically from those of older adults (OAs) is unclear. We analyzed paired tumor-normal whole-genomes from 698 AYAs and 5,220 OAs, with subcohorts matched by cancer group to disentangle age from tumor type. AYA tumors carried fewer somatic variants yet largely shared the same genetic drivers; many apparent age differences reflected age-dependent cancer subtypes, such as IDH-mutant glioma and HPV-positive cervical cancer. Colibactin, APOBEC and homologous recombination deficiency-associated signatures were more prevalent in AYA colorectal, gynecological and breast cancers, respectively, but were not more mutagenic when present, suggesting earlier-life activity rather than AYA-specific mutagenesis. Tumor type-concordant pathogenic germline variants were enriched in AYAs (10.9% overall versus 6.6% in matched OAs; p=0.006), often with a somatic second hit. Age thus shaped AYA cancer genomes through mutational processes, subtype composition and germline predisposition, supporting comprehensive tumor-normal profiling beyond driver-focused testing.

cancer biology↗

bioRxiv2025

Systematic identification of genomic non-response biomarkers to cancer therapies

The costs of cancer therapies are rising rapidly across the globe, with novel therapies like targeted treatment and immunotherapies as major contributors, but their effectiveness can be low or uncertain due to limited post market surveillance. Reliable biomarkers to identify patients highly unlikely to respond to cancer therapies represent an increasingly important clinical and societal need, as they could prevent unnecessary treatments, reduce side effects, and alleviate pressure on healthcare systems. Here, we developed a robust statistical framework and applied it to whole-genome and transcriptome sequencing data of cancer patients (n = 2,596) with advanced disease. Our approach systematically identified known and potentially novel genomic and transcriptomic biomarkers of non-response, such as immune evasion driver events in skin melanoma patients treated with anti-PD-1 checkpoint inhibitors, and KRASG12 mutations in metastatic colorectal cancer patients treated with different chemotherapy regimens. Despite the identification of these promising non-response signals, an analytical power analysis revealed that for most treatments and/or cancer types the cohort sizes are underpowered. Our results underscore the promises and the urgent need for expanding response-annotated real-world comprehensive genomics datasets to enable robust biomarker identification and validation.

genomics↗

bioRxiv2018

Pan-cancer whole genome analyses of metastatic solid tumors

Metastatic cancer is one of the major causes of death and is associated with poor treatment efficiency. A better understanding of the characteristics of late stage cancer is required to help tailor personalised treatment, reduce overtreatment and improve outcomes. Here we describe the largest pan-cancer study of metastatic solid tumor genomes, including 2,520 whole genome-sequenced tumor-normal pairs, analyzed at a median depth of 106x and 38x respectively, and surveying over 70 million somatic variants. Metastatic lesions were found to be very diverse, with mutation characteristics reflecting those of the primary tumor types, although with high rates of whole genome duplication events (56%). Metastatic lesions are relatively homogeneous with the vast majority (96%) of driver mutations being clonal and up to 80% of tumor suppressor genes bi-allelically inactivated through different mutational mechanisms. For 62% of all patients, genetic variants that may be associated with outcome of approved or experimental therapies were detected. These actionable events were distributed across various mutation types underlining the importance of comprehensive genomic tumor profiling for cancer precision medicine.

cancer biology↗